<DOC>
	<DOCNO>NCT01105780</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics ( drug absorb body , distribute within body remove body time ) pharmacodynamics ( effect drug ) JNJ-41443532 healthy male female Caucasian male Japanese participant .</brief_summary>
	<brief_title>JNJ-41443532 Sex , Race , Age Pharmacokinetic ( PK ) Study</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither physician participant know name assigned drug ) , placebo-controlled , parallel group , single dose study male female Caucasian male Japanese participant . The purpose study assess safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) study healthy male female caucasian male Japanese participant . For participant , study consist screen examination ( within 28 day first dose Day 1 ) , single period open label treatment ( people involve know identity intervention ) upon entry study discharge Day 3 ) , final , follow-up examination 7-10 day discharge study . Safety assessment include monitor adverse event , evaluation lab result , cardiac parameter , vital sign , physical exam . Participants receive study medication ( JNJ-41443532 placebo ) mouth Day 1 overnight fast least 10 hour ; plan dose 250 mg .</detailed_description>
	<criteria>Caucasian Japanese male Japanese participant born Japan Japanese parent maternal paternal grandparent must live outside Japan 5 year , lifestyles include diet , must change significantly since relocate Japan Caucasian male postmenopausal/surgically sterile Caucasian female Caucasian participant bear Caucasian parent maternal paternal grandparent must continue usual lifestyle diet Weight = 50 kilogram Body Mass Index ( BMI ) 18.5 29.9 kg/m2 ( inclusive ) Healthy basis physical examination , medical history , vital sign , electrocardiogram ( ECG ) clinical laboratory test perform screen Men must agree use double barrier method birth control ( e.g . condom use spermicide diaphragm , hormonal contraceptive intrauterine device female partner ) donate sperm study 3 month receive last dose study drug Willing adhere prohibition restriction specify protocol Competency speak comprehend language study conduct History , currently active , significant illness medical disorder , include ( limited ) cardiovascular disease ( include cardiac arrhythmia , myocardial infarction , stroke , peripheral vascular disease ) , endocrine metabolic disease ( e.g . hyper/hypothyroidism ) , hematological disease ( e.g . von Willebrand 's disease bleeding disorder ) , respiratory disease , hepatic gastrointestinal disease , neurological psychiatric disease , ophthalmologic disorder ( include retinal disorder cataract ) , neoplastic disease , skin disorder , illness Investigator considers exclude participant Participants risk QTc prolongation ( specific heart rhythm irregularity ) Within 12 month prior screen , clinically important , serious infection ( e.g . hepatitis , pneumonia , pyelonephritis ) , hospitalize infection treat intravenous ( IV ) antibiotic infection Smoker tobacco user within past 3 month History alcohol drug abuse History clinically significant drug and/or food allergy , include allergy intolerance ( e.g . lactose intolerance ) Donation 1 unit blood acute loss equivalent amount blood within 60 day prior study drug administration Received experimental drug use experimental medical device within 60 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Healthy</keyword>
	<keyword>Japanese</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>JNJ-41443532</keyword>
</DOC>